Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Ultrasound II: Endoscopic Ultrasound and FibroScan01:25

Ultrasound II: Endoscopic Ultrasound and FibroScan

337
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
337
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

106
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
106
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

113
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
113

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

DNMT1 Facilitates the Progression of MASLD by Impeding Transcription Mediated by HNF4α and PPARα.

Clinical and molecular hepatology·2026
Same author

Emotional and behavioral problems associated with food addiction in children and adolescents with obesity.

Obesity research & clinical practice·2025
Same author

Integrative transcriptomic analysis identifies emetine as a promising candidate for overcoming acquired resistance to ALK inhibitors in lung cancer.

Molecular oncology·2024
Same author

Which obesity index is the most useful marker for predicting hepatic steatosis in children and adolescents with obesity? A cross-sectional study using quantitative magnetic resonance imaging.

Obesity research & clinical practice·2023
Same author

The infusion of ex vivo, interleukin-15 and -21-activated donor NK cells after haploidentical HCT in high-risk AML and MDS patients-a randomized trial.

Leukemia·2023
Same author

Epigenetic Activation of Tensin 4 Promotes Gastric Cancer Progression.

Molecules and cells·2023

Related Experiment Video

Updated: Nov 29, 2025

Analysis of Liver Microenvironment During Early Progression of Non-Alcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in Zebrafish
09:27

Analysis of Liver Microenvironment During Early Progression of Non-Alcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in Zebrafish

Published on: April 1, 2021

3.8K

EZH2 as a Potential Target for NAFLD Therapy.

Hyun Jung Lim1,2, Mirang Kim1,2

  • 1Personalized Genomic Medicine Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon 34141, Korea.

International Journal of Molecular Sciences
|November 19, 2020
PubMed
Summary

Non-alcoholic fatty liver disease (NAFLD) involves epigenetic changes. Enhancer of zeste homolog 2 (EZH2) dysregulation promotes NAFLD, suggesting EZH2 inhibitors as a potential therapeutic strategy for this complex liver condition.

Keywords:
EZH2NAFLDNASHepigeneticsliver fibrosis

More Related Videos

Inducing and Characterizing Vesicular Steatosis in Differentiated HepaRG Cells
09:15

Inducing and Characterizing Vesicular Steatosis in Differentiated HepaRG Cells

Published on: July 18, 2019

9.2K
Development of an Ethanol-induced Fibrotic Liver Model in Zebrafish to Study Progenitor Cell-mediated Hepatocyte Regeneration
10:42

Development of an Ethanol-induced Fibrotic Liver Model in Zebrafish to Study Progenitor Cell-mediated Hepatocyte Regeneration

Published on: May 13, 2016

9.4K

Related Experiment Videos

Last Updated: Nov 29, 2025

Analysis of Liver Microenvironment During Early Progression of Non-Alcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in Zebrafish
09:27

Analysis of Liver Microenvironment During Early Progression of Non-Alcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in Zebrafish

Published on: April 1, 2021

3.8K
Inducing and Characterizing Vesicular Steatosis in Differentiated HepaRG Cells
09:15

Inducing and Characterizing Vesicular Steatosis in Differentiated HepaRG Cells

Published on: July 18, 2019

9.2K
Development of an Ethanol-induced Fibrotic Liver Model in Zebrafish to Study Progenitor Cell-mediated Hepatocyte Regeneration
10:42

Development of an Ethanol-induced Fibrotic Liver Model in Zebrafish to Study Progenitor Cell-mediated Hepatocyte Regeneration

Published on: May 13, 2016

9.4K

Area of Science:

  • Hepatology
  • Epigenetics
  • Molecular Biology

Background:

  • Non-alcoholic fatty liver disease (NAFLD) is a complex condition influenced by genetics and epigenetics.
  • Epigenetic pathway deregulation is common in NAFLD, offering potential therapeutic targets.
  • Enhancer of zeste homolog 2 (EZH2) is a key epigenetic regulator involved in gene silencing.

Purpose of the Study:

  • To review the current understanding of EZH2's role in NAFLD pathogenesis.
  • To explore the potential of EZH2 as a therapeutic target for NAFLD treatment.

Main Methods:

  • Review of existing literature on EZH2 function in liver biology and NAFLD.
  • Analysis of studies investigating EZH2 inhibitors in vitro and in clinical trials.

Main Results:

  • EZH2 plays critical roles in liver development, homeostasis, and regeneration.
  • Aberrant EZH2 activation is linked to the progression of NAFLD.
  • Several EZH2 inhibitors have been developed and are under investigation.

Conclusions:

  • EZH2 is implicated in the progression of NAFLD.
  • Targeting EZH2 presents a promising novel therapeutic avenue for NAFLD treatment.